Researchers: Majority of patients with Alzheimer’s disease would not have been eligible for clinical trials of new controversial Alzheimer’s drug    

In a research letter in JAMA, physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) found that the vast majority of patients who had a diagnosis of either cognitive impairment, Alzheimer’s disease, or Alzheimer’s disease related disorders, including cardiovascular disease, prior stroke, use of blood thinners, and age over 85 years, would have been excluded them from the aducanumab clinical trials.

NeuroVision Imaging Inc. Announces Additional Funding From the ADDF to Accelerate Development of Novel Blood-Based Lab Test to Predict Dementia Before Clinical Onset

NeuroVision Imaging Inc. has received an additional investment from the Alzheimer’s Drug Discovery Foundation to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer’s disease and other dementias before clinical onset.

Do Some Diabetes Drugs Reduce the Risk of Alzheimer’s?

MINNEAPOLIS – People taking certain drugs to lower blood sugar for type 2 diabetes had less amyloid in the brain, a biomarker of Alzheimer’s disease, when compared to both people with type 2 diabetes not taking the drugs and people without diabetes. The new study, published in the August 11, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology, also found people taking these drugs, called dipeptidyl peptidase-4 inhibitors, showed slower cognitive decline than people in the other two groups.

Self-reported declines in cognition may be linked to changes in brain connectivity

A team from Wayne State University recently published the results of a three-year study of cognitive changes in older adults who complained that their cognitive ability was worsening though clinical assessments showed no impairments. MRIs at 18-month intervals showed significant changes in functional connectivity in two areas of the brain.

Renowned Alzheimer’s Clinical Trials Researcher Available to Comment on June 7 FDA Approval of Aducanumab

The Food and Drug Administration on June 7 approved Aducanumab, which will carry the brand name Aduhelm, as the first new treatment for Alzheimer’s disease in nearly 20 years. Dr. Jeffrey L. Cummings, UNLV research professor and leading expert on Alzheimer’s clinical trials, calls…

CUR Health Sciences Division Announces 2021 Mentor Awardees

The Health Sciences Division of the Council on Undergraduate Research announces the 2021 recipients of its Mentor Awards, which honor exceptional mentoring and advising by higher education faculty across all subdivisions of health sciences.

Nanoparticles Help Untangle Alzheimer’s Disease Amyloid Beta Plaques

ROCKVILLE, MD – Scientists are still a long way from being able to treat Alzheimer’s Disease, in part because the protein aggregates that can become brain plaques, a hallmark of the disease, are hard to study.

NeuroVision Imaging Inc., Announces New Funding From the ADDF to Develop Affordable, Accessible Biomarkers to Diagnose Alzheimer’s and Related Dementias

NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders.

Coconut Oil’s Benefits to Alzheimer’s Ignored in N.Y. Times Attack, Says Dr. Leslie Norins of

Although cardiologists often decry coconut oil because of certain fats it contains, they overlook the growing evidence that other fatty constituents, especially medium-chain triglycerides, may alleviate some cases of mild cognitive impairment and Alzheimer’s disease

How Caregivers of People with Dementia Can Navigate Holidays During the Pandemic

As COVID-19 cases increase across the nation, many caregivers are trying to navigate the holidays for relatives with dementia or Alzheimer’s disease. The Centers for Disease Control and Prevention suggests that people not travel to limit the potential spread of the coronavirus.

Mary Catherine Lundquist, program director of Care2Caregivers, a peer counseling helpline (800-424-2494) for caregivers of people with dementia and Alzheimer’s disease operated by Rutgers Behavioral Health Care, discusses how families can stay connected with their loved ones.

Researchers Discover Neuroprotective Treatment for Chronic Traumatic Brain Injury

Traumatic brain injury (TBI) is a leading cause of cognitive impairment that affects millions of people worldwide. Despite growing awareness about the debilitating and lifelong progressive consequences of TBI, there are currently no treatments that slow the deteriorative process. TBI survivors are currently treated with extensive physical and cognitive rehabilitation, accompanied by medications that may mitigate symptoms yet do not halt or slow neurodegeneration. Now, researchers have found for the first time that this process can be pharmacologically reversed in an animal model of this chronic health condition, offering an important proof of principle in the field and a potential path to new therapy.

What Factors Help Predict Who Will Keep Their Memory into Their 90s?

Why do some people stay sharp into their 90s, even if they have the amyloid plaques in the brain that are associated with Alzheimer’s disease? And why do others reach their 90s without ever developing any plaques? These questions are explored in a new study published in the July 22, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Blood Vessel Defects in Eyes May Foretell Alzheimer’s

Alzheimer’s disease in its early stages affects the integrity of small blood vessels in the retinas of patients, according to a recent study led by Cedars-Sinai. This discovery holds promise for early diagnosis of Alzheimer’s through the retina, a back-of-the-eye organ that is an extension of the brain and easily accessible for live, noninvasive imaging.

How to Help Loved Ones with Dementia Cope During COVID-19

The COVID-19 pandemic and resulting social isolation present unique challenges for more than five million Americans living with Alzheimer’s disease and their caregivers. Monica Townsend, training and consultation specialist at the Comprehensive Services on Aging at Rutgers University Behavioral Health Care, shares how caregivers can cope through the health crisis:

Upended Caregiving Impact for 5M+ Americans with Alzheimer’s, Caregivers

The COVID-19 pandemic is presenting unique challenges for 5M+ Americans living with Alzheimer’s and their caregivers. The recent upending of traditional caregiving resources and structures, across home, adult day services, residential and assisted living facilities and nursing homes, has created new challenges for caregivers. Data from the Alzheimer’s Association indicates 48% of nursing home residents are living with Alzheimer’s or other dementias and among older adults in residential care settings, including assisted living, 42% or more have some form of dementia. Still others receive community-based services, including 32% of individuals using home health services and 31% using adult day services.

The Alzheimer’s Association continues to offer free care and support for families through 24/7 Helpline (800.272.3900) staffed by clinical experts, while local support groups are now being offered via virtual channels for the foreseeable future. Experts including Harry Johns, president

Primary Care Physicians on the Front Lines of Diagnosing and Providing Alzheimer’s and Dementia Care: Half Say Medical Profession Not Prepared to Meet Expected Increase in Demands

– Report provides latest Alzheimer’s prevalence, incidence, mortality and costs of care data –
– Barring medical breakthroughs, the number of people age 65+ with Alzheimer’s dementia may nearly triple by 2050 –

AI-analyzed blood test can predict the progression of neurodegenerative disease

Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.

Kim Campbell, Alzheimer’s disease advocate and widow of music legend Glen Campbell, to keynote ANA2019 October 13

WHO: Kim Campbell, Alzheimer’s disease advocate and widow of Grammy Hall of Fame and Award-winning music legend Glen Campbell; and ANA President David Holtzman, MD, ANA President, Professor and Chairman of the Department of Neurology at the Washington University School…

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center

The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.